Skip to main content
. 2021 May 17;131(10):e146832. doi: 10.1172/JCI146832

Figure 6. ATT-I enhances the immune checkpoint blockade immune responses.

Figure 6

(A–C) Effects of the ATT-I (daily) and anti–PD-1 (3 times/week, 5 injections in total) on tumor growth (A) and tumor volume (B) of MC38-derived tumors in the subcutaneous C57BL/6 mouse model. Error bars represent SEM (n = 10 mice per group). Data shown are 1 representative of 2 independent experiments. Statistical analysis was conducted using 2-way ANOVA (A) and 1-way ANOVA (B). Pictures of the resected tumors (C). Scale bar: 1 cm. (D and E) Effects of the ATT-I (50 mg/kg, daily) and anti–PD-1 (200 μg/mouse, 3 times/week, 5 injections in total) on tumor growth, measured via bioluminescence imaging (F) and survival (G) on the orthotopic MC38-derived tumor model (log-rank test). Each group includes 5 mice. (F) Tumor growth curves of MC38-derived tumors with or without PSMD4 knockdown and treated with anti–PD-1 only or anti–PD-1 together with ATT-I (combo). Each group includes 6 mice. Statistical analysis was conducted using 2-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.